NO996572L - Nye substituerte imidazolforbindelser - Google Patents

Nye substituerte imidazolforbindelser

Info

Publication number
NO996572L
NO996572L NO996572A NO996572A NO996572L NO 996572 L NO996572 L NO 996572L NO 996572 A NO996572 A NO 996572A NO 996572 A NO996572 A NO 996572A NO 996572 L NO996572 L NO 996572L
Authority
NO
Norway
Prior art keywords
imidazole compounds
substituted imidazole
new substituted
new
compounds
Prior art date
Application number
NO996572A
Other languages
English (en)
Norwegian (no)
Other versions
NO996572D0 (no
Inventor
Jerry L Adams
Ralph Floyd Hall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO996572D0 publication Critical patent/NO996572D0/no
Publication of NO996572L publication Critical patent/NO996572L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
NO996572A 1997-07-02 1999-12-30 Nye substituerte imidazolforbindelser NO996572L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5159297P 1997-07-02 1997-07-02
PCT/US1998/013809 WO1999001130A1 (fr) 1997-07-02 1998-07-01 Nouveaux composes d'imidazole substitue

Publications (2)

Publication Number Publication Date
NO996572D0 NO996572D0 (no) 1999-12-30
NO996572L true NO996572L (no) 1999-12-30

Family

ID=21972242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996572A NO996572L (no) 1997-07-02 1999-12-30 Nye substituerte imidazolforbindelser

Country Status (22)

Country Link
EP (2) EP1014976B1 (fr)
JP (2) JP2002507992A (fr)
KR (1) KR20010014420A (fr)
CN (1) CN1134420C (fr)
AR (1) AR016294A1 (fr)
AT (1) ATE290001T1 (fr)
AU (1) AU8381298A (fr)
BR (1) BR9810342A (fr)
CA (2) CA2294522A1 (fr)
CO (1) CO4950624A1 (fr)
CZ (1) CZ9904750A3 (fr)
DE (2) DE69829192T2 (fr)
ES (2) ES2207847T3 (fr)
HU (1) HUP0002050A3 (fr)
IL (3) IL133035A0 (fr)
NO (1) NO996572L (fr)
NZ (1) NZ500922A (fr)
PL (1) PL337738A1 (fr)
TR (1) TR200000014T2 (fr)
TW (1) TW536539B (fr)
WO (2) WO1999001130A1 (fr)
ZA (1) ZA985763B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002502380A (ja) 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
WO1998056377A1 (fr) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Nouveaux composes de pyrazole et de pyrazoline substitues
WO1998057966A1 (fr) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Nouveaux composes imidazole a substitution d'aryloxypymiridine
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999017776A1 (fr) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Nouveaux composes substitues de cycloalcenyle
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1112070B1 (fr) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Nouveaux composes de triazole substitues
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7053099B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
WO2001038314A1 (fr) 1999-11-23 2001-05-31 Smithkline Beecham Corporation Composes de 3,4-dihydro-(1h)quinazolin-2-one utilises comme inhibiteurs de kinase csbp/p38
JP2003528043A (ja) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）キナゾリン−２−オン化合物
EA008242B1 (ru) 1999-12-08 2007-04-27 Фармация Корпорейшн Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2004004725A2 (fr) * 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouvelles compositions pharmaceutiques a base de nouveaux anticholinergiques et d'inhibiteurs de la kinase p38
AU2003291227A1 (en) 2002-11-05 2004-06-07 Smithkline Beecham Corporation Antibacterial agents
PE20050676A1 (es) 2003-12-12 2005-11-02 Wyeth Corp Quinolinas referidas a enfermedades cardiovasculares
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
TWI326282B (en) 2004-04-28 2010-06-21 Mitsubishi Tanabe Pharma Corp Heterocyclic compound
KR100793479B1 (ko) * 2004-04-28 2008-01-14 다나베 미츠비시 세이야꾸 가부시키가이샤 염증성 질환을 치료하기 위한 ｐ３８ ＭＡＰ- 키나제억제제로서의４-２-(시클로알킬아미노)피리딘-4-일-(페닐)-이미다졸린-2-온 유도체
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
WO2006062110A1 (fr) * 2004-12-06 2006-06-15 Banyu Pharmaceutical Co., Ltd. Derive de la piperazine
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CA2627497C (fr) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Compose amide heterocyclique et utilisation de celui-ci
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
CA2890018A1 (fr) * 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Derives indol-5-ole substitues et leurs applications therapeutiques
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Utilisation d'inhibiteurs de p38 pour réduire l'expression de dux4
CA3159250A1 (fr) * 2019-11-29 2021-06-03 Facio Intellectual Property B.V. Nouveaux composes pour le traitement de maladies liees a l'expression de dux4
US20230271953A1 (en) * 2019-11-29 2023-08-31 Facio Intellectual Property B.V. Novel compounds for treatment of diseases related to DUX4 expression

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ188244A (en) * 1977-09-13 1981-04-24 Ici Australia Ltd 2-substituted pyrimidines compositions growth regulating processes
CA1175431A (fr) * 1980-07-25 1984-10-02 Alfred Sallmann Derives tri-substitues d'imidazole, methode de preparation, compositions pharmaceutiques qui en renferment et applications
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
JPH082883B2 (ja) * 1986-06-06 1996-01-17 クミアイ化学工業株式会社 ２−フエノキシピリミジン誘導体および除草剤
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
NZ302117A (en) * 1995-01-12 1999-10-28 Smithkline Beecham Corp 1-cycloalkyl or cycloalkylalkyl 4,5-trisubstituted imidazole derivatives and medicaments
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
TR199801361T2 (xx) * 1996-01-11 1998-10-21 Smithkline Beecham Corporation Yeni ikameli imidazol bile�imleri.
JP2000507224A (ja) * 1996-03-08 2000-06-13 スミスクライン・ビーチャム・コーポレイション Ｃｓａｉｄ化合物の血管形成の抑制物質としての使用
WO1997035856A1 (fr) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Nouveau traitement des lesions du systeme nerveux central

Also Published As

Publication number Publication date
IL133035A0 (en) 2001-03-19
HUP0002050A3 (en) 2002-04-29
AU8381598A (en) 1999-01-25
CO4950624A1 (es) 2000-09-01
DE69829192T2 (de) 2006-02-16
ATE290001T1 (de) 2005-03-15
NZ500922A (en) 2001-12-21
JP2002507992A (ja) 2002-03-12
DE69818266D1 (de) 2003-10-23
IL190216A0 (en) 2008-11-03
WO1999001130A1 (fr) 1999-01-14
IL190215A0 (en) 2008-11-03
TR200000014T2 (tr) 2000-11-21
NO996572D0 (no) 1999-12-30
ZA985763B (en) 1999-01-19
EP0996446B1 (fr) 2003-09-17
HUP0002050A2 (hu) 2001-04-28
EP0996446A4 (fr) 2001-08-29
ES2207847T3 (es) 2004-06-01
DE69829192D1 (de) 2005-04-07
CN1134420C (zh) 2004-01-14
CA2294522A1 (fr) 1999-01-14
AR016294A1 (es) 2001-07-04
CA2294524A1 (fr) 1999-01-14
CN1261277A (zh) 2000-07-26
EP0996446A1 (fr) 2000-05-03
EP1014976A4 (fr) 2001-08-29
WO1999001131A1 (fr) 1999-01-14
TW536539B (en) 2003-06-11
PL337738A1 (en) 2000-08-28
EP1014976A1 (fr) 2000-07-05
ES2237843T3 (es) 2005-08-01
KR20010014420A (ko) 2001-02-26
EP1014976B1 (fr) 2005-03-02
AU737637B2 (en) 2001-08-23
CZ9904750A3 (cs) 2001-12-12
JP2002507994A (ja) 2002-03-12
BR9810342A (pt) 2000-09-05
AU8381298A (en) 1999-01-25
DE69818266T2 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
NO996572D0 (no) Nye substituerte imidazolforbindelser
NO983181L (no) Nye substituerte imidazolforbindelser
NO20000226D0 (no) Nye spiroazabicykliske heterocykliske forbindelser
NO20005878L (no) Nye 2-alkylsubstituerte imidazolforbindelser
IS5354A (is) Ný efnasambönd
BR9612465A (pt) Compostos heterocíclicos
DK0861235T3 (da) Substituerede benzylaminopiperidinforbindelser
ID18759A (id) Imidazole tersubstitusi sikloalkil baru
ID19609A (id) Senyawa-senyawa heterosiklik
NO20001938D0 (no) Nye aryloksy-alkyl-dialkylaminer
ID18685A (id) Senyawa trisiklik tersubstitusi
NO974605D0 (no) Nye heterosykliske forbindelser
FI973207A7 (fi) Heterosyklisiä yhdisteitä
NO981216L (no) Nye heterosykliske forbindelser
ID22983A (id) Senyawa-senyawa fluorometoksimino
EE9900466A (et) Ühendid
NO995430D0 (no) Nye heterosykliske forbindelser
NO994838L (no) <pi>-kompleks-forbindelser
DK0851865T3 (da) Hidtil ukendte heterocykliske forbindelser
SE9702535D0 (sv) New compounds
SE9704839D0 (sv) New compounds
SE9703225D0 (sv) new compounds
SE9702696D0 (sv) New compounds
SE9702378D0 (sv) New compounds
SE9702747D0 (sv) New compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application